期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 54, 期 19, 页码 1787-1794出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2009.06.036
关键词
carotid; atherosclerosis; HDL cholesterol; magnetic resonance imaging
资金
- Merck KGaA
- Merck
- GlaxoSmithKline
- AstraZeneca
- Sanofi
- Solvay
- Wellcome Trust
- Oxford Comprehensive Biomedical Research Centre
- National Institute for Health Research
- National Institute for Health Research [NF-SI-0508-10247] Funding Source: researchfish
Objectives Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function. Background NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density lipoprotein cholesterol and is widely used as an adjunct to statin therapy in patients with coronary artery disease. Although changes in plasma lipoproteins suggest potential benefit, there is limited evidence of the effects of NA on disease progression when added to contemporary statin treatment. Methods We performed a double-blind, randomized, placebo-controlled study of 2 g daily modified-release NA added to statin therapy in 71 patients with low HDL-C (< 40 mg/dl) and either: 1) type 2 diabetes with coronary heart disease; or 2) carotid/peripheral atherosclerosis. The primary end point was the change in carotid artery wall area, quantified by magnetic resonance imaging, after 1 year. Results NA increased HDL-C by 23% and decreased low-density lipoprotein cholesterol by 19%. At 12 months, NA significantly reduced carotid wall area compared with placebo (adjusted treatment difference: -1.64 mm(2) [95% confidence interval: -3.12 to -0.16]; p = 0.03). Mean change in carotid wall area was -1.1 +/- 2.6 mm(2) for NA versus +1.2 +/- 3.0 mm(2) for placebo. In both the treatment and placebo groups, larger plaques were more prone to changes in size (r = 0.4, p = 0.04 for placebo, and r = -0.5, p = 0.02 for NA). Conclusions In statin-treated patients with low HDL-C, high-dose modified- release NA, compared with placebo, significantly reduces carotid atherosclerosis within 12 months. (Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function; NCT00232531) (J Am Coll Cardiol 2009;54:1787-94) (c) 2009 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据